diabetes

Tirzepatide trial shows additional 21.1% weight loss following intensive lifestyle intervention

A Vanderbilt clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.

Dame Frances Ashcroft Discovery Lecture postponed

From left, Sheila Collins, PhD, Ryan Ceddia, PhD, and Heidi Hamm, PhD, and their colleagues have identified a potential new approach to reducing the global impact of obesity and diabetes. (photo by Erin O. Smith)

Releasing a brake that drives obesity and diabetes

Vanderbilt researchers have uncovered a potential new way to help curb the rapidly rising worldwide prevalence of metabolic disorders, including obesity and diabetes.

Update: Dame Frances Ashcroft to deliver Sept. 14 Vanderbilt Prize Lecture

Renowned diabetes expert Professor Dame Frances Ashcroft, recipient of the 2023 Vanderbilt Prize in Biomedical Science, will deliver her Vanderbilt Prize Discovery Lecture at 4 p.m. Thursday, Sept. 14, in 208 Light Hall.

VUMC receives $28 million to lead national study of COVID-diabetes link

Researchers at Vanderbilt University Medical Center have received a four-year, $28 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to study the relationship between COVID-19 and diabetes.

The urgency of research

Griffin Rodgers, MD, director of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, described the urgency of the nation’s diabetes epidemic July 26 during a symposium of the NIDDK Medical Student Research Program in Diabetes and Obesity hosted by Vanderbilt University.

1 2 3 4 18